Lyn­dra’s long-act­ing risperi­done for­mu­la­tion hits PhI­II schiz­o­phre­nia tri­al end­points

Lyn­dra Ther­a­peu­tics’ schiz­o­phre­nia drug can­di­date has passed its late-stage clin­i­cal test ac­cord­ing to in­ter­im da­ta, prompt­ing an ear­ly end to the study and prepa­ra­tions for a reg­is­tra­tional safe­ty tri­al.

The Phase III STAR­LYNG-1 tri­al was de­signed to test once-week­ly LYN-005 against stan­dard of care dai­ly Risperdal in 90 peo­ple with schiz­o­phre­nia or schizoaf­fec­tive dis­or­der. LYN-005 con­tains the same ac­tive in­gre­di­ent as Risperdal — risperi­done — but was de­signed for once-week­ly dos­ing us­ing Lyn­dra’s LYNX drug de­liv­ery plat­form

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER